We observed a higher Mex3a promoter methylation level in HCC patients with ascites compared with patients without ascites, which may be because Mex3a can promote tumor progression and affect prognosis (Wang et al., 2023). This evidence concerns the gene MEX3A and hepatocellular carcinoma.